Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's research. The company showcased new data on eMTBR-Tau and BD-pTau217 biomarkers, which improve early detection and disease staging by analyzing multiple proteins simultaneously. This advancement could lead to more precise and earlier Alzheimer's diagnosis, with further insights expected from Alamar's upcoming AAIC workshop. The platform's sensitivity surpasses current market technologies, positioning Alamar as a leader in precision proteomics for neurodegenerative diseases.
Shield Therapeutics has agreed to take full commercial control of its oral iron therapy ACCRUFeR in the US from Viatris starting September 30, without any upfront payment. Instead, Shield will pay reduced royalties on US sales over five years. This m...
Autohome reported Q2 2026 results in line with expectations but faces significant challenges due to declining auto sales and reduced dealer advertising budgets in China. Its traditional vertical advertising model is under pressure from alternative pl...
Bread Financial Holdings, formerly Alliance Data, is a U.S. financial services firm specializing in consumer payment and lending solutions. It maintains a strong financial position with a Tier 1 capital ratio near 14% and BB credit ratings, funding i...
BlackRock has purchased over $3.1 billion worth of Bitcoin and Ethereum in just eight days, acquiring 22,722 BTC and 385,633 ETH. This surge in buying coincides with a strong recovery in the broader cryptocurrency market. BlackRock's crypto funds, in...
Marvell Technology reported Q2 earnings and revenue above Wall Street expectations, with data center revenue up 46% year-over-year to $2.17 billion, driven by robust AI-related bookings. Despite this, shares fell 8% in premarket trading as investors ...
